Spark Biomedical Completes Enrollment for Groundbreaking Trial
Spark Biomedical has completed enrollment for its Phase II clinical trial exploring a non-invasive therapy for Neonatal Opioid Withdrawal Syndrome (NOWS). The study, funded by NIDA’s HEAL Initiative, evaluates how transcutaneous auricular neurostimulation (tAN®) can reduce opioid use in newborns. Conducted at leading institutions including MUSC, UT Southwestern, and UT Health San Antonio, the trial focused on infants over 33 weeks gestational age. Early results show promise in reducing withdrawal symptoms and shortening hospital stays. Participants will be followed for two years to assess long-term neurodevelopmental outcomes.
Spark Biomedical Completes Enrollment for Groundbreaking Trial